TYRO3 agonist as therapy for glomerular disease

TYRO3 agonist as therapy for glomerular disease

Podocyte injury and loss are key drivers of primary and secondary glomerular diseases, such as focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease (DKD). We previously demonstrated the renoprotective role of protein S (PS) and its cognate tyrosine-protein kinase receptor, TYRO3, in...

Full description

Bibliographic Details
Main Authors: Fang Zhong, Hong Cai, Jia Fu, Zeguo Sun, Zhengzhe Li, David Bauman, Lois Wang, Bhaskar Das, Kyung Lee, John Cijiang He
Format: Article
Language:English
Published: American Society for Clinical investigation 2023-01-01
Series:JCI Insight
Subjects:
Nephrology
Online Access:https://doi.org/10.1172/jci.insight.165207

Internet

https://doi.org/10.1172/jci.insight.165207

Similar Items